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Background: Cost-related medication nonadherence (CRMNA) refers to not taking medications as prescribed because
of difficulties paying for them. Objectives: The aims of this study were (1) to assess the prevalence of CRMNA to
immunosuppressants in heart transplant recipients internationally and (2) to determine multilevel correlates (patient,
center, and healthcare system levels) of CRMNA.Methods: Using data from the cross-sectional international BRIGHT
study, applying multistaged sampling, CRMNA was assessed via 3 self-report items in 1365 patients from 36 heart
transplant centers in 11 countries. Cost-relatedmedication nonadherence was defined as any positive answer on any of
the 3 items. Healthcare system–level (ie, insurance coverage, out-of-pocket expenditures) and patient-level (ie,
intention, perceived financial burden, cost as a barrier, a health belief regarding medication benefits, cost-related
self-efficacy, and demographic factors) CRMNA correlates were assessed. Correlates were examined using mixed
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logistic regression analysis. Results: Across all study countries, CRMNA had an average prevalence of 2.6% (range, 0%
[Switzerland/Brazil] to 9.8% [Australia]) and was positively related to being single (odds ratio, 2.29; 95% confidence
interval, 1.17–4.47), perceived financial burden (odds ratio, 2.15; 95% confidence interval, 1.55–2.99), and cost as a
barrier (odds ratio, 2.60; 95% confidence interval, 1.66–4.07). Four protective factors were identified: white ethnicity
(odds ratio, 0.37; 95% confidence interval, 0.19–0.74), intention to adhere (odds ratio, 0.44; 95% confidence interval,
0.31–0.63), self-efficacy (odds ratio, 0.54; 95% confidence interval, 0.43–0.67), and belief about medication benefit
(odds ratio, 0.70; 95% confidence interval, 0.57–0.87). Regarding variability, 81.3%was explained at the patient level;
13.8%, at the center level; and 4.8%, at the country level. Conclusion: In heart transplant recipients, the CRMNA
prevalence varies across countries but is lower than in other chronically ill populations. Identified patient-level correlates
are novel (ie, intention to adhere, cost-related barriers, and cost-related self-efficacy) and indicate patient-perceived
medication cost burden.
KEY WORDS: healthcare costs, heart transplantation, medication adherence, multilevel correlates
Heart transplant recipients depend on lifelong im-munosuppressive (IS) and co-medication regimens1,2;
however, nonadherence is common. Occurring in 14.5
cases per 100 persons per year,3 it is associated with
poor clinical and economic outcomes.4–7 One likely factor
is medication cost, which patients' health insurance may
cover fully, partially, or not at all.8
Cost-related medication nonadherence (CRMNA)
consists of 3 behaviors, namely, not filling a prescription
and skipping or reducing doses because of their cost,9 and
is a distinct concept from medication nonadherence as
defined by theABC taxonomy10 (the prevalence and deter-
minants of the latter have previously been reported as part
of the BRIGHT study).11,12 The 2014 Commonwealth
Fund InternationalHealth Policy Survey ofOlder Adults
assessed CRMNA, defined as either not filling a pre-
scription or skipping doses within the last 12 months
because of out-of-pocket (OOP) costs.13 The lowest
nonadherence rates occurred in France, Norway,
Sweden, Switzerland, and the United Kingdom (<3%);
the highest were observed in the United States (16.8%),
Canada (8.3%), and Australia (6.8%).13,14 Nonadherence
correlates with cost; for example, 41% of chronically ill pa-
tients in the United States have monthly OOP medication
expenses exceeding 1000 USD, and only 2% of those
in Sweden do.14
In transplantation, CRMNA issues focus primarily
on the United States,15–18 which has both the lowest
proportion of health-insured patients and the highest
OOP medication burden of all developed nations.14,15,18
In a survey of 254 US adult and pediatric transplant
programs regarding IS-related cost issues,17 83% of
the transplant programs reported that patients fre-
quently contacted themwith concerns about their med-
ication costs. More than 70% of surveyed centers
indicated that at least every fifth patient had difficulties
affording ISs,17 andmore than two-thirds (68%) attrib-
uted deaths and graft losses to CRMNA.17 However,
CRMNA prevalence in heart transplantation and over-
all transplant populations in international (including
US) samples remains unexplored.
For patients with cardiovascular disease (N = 1849;
>40 years old), CRMNA's relevance was shown in a
2016 study conducted inWestern Canada. With roughly
80% of the sample reporting OOP spending on medi-
cation, the CRMNA rate was 4.1% (95% confidence
interval, 2.6–6.3). Almost 5% of the sample spent at
least 5% of their household income OOP for medications.
These patients were significantly more likely to report
CRMNA than were those spending less than 5%.19
Understanding CRMNA and identifying at-risk patients
require a clearer knowledge of its determinants and/or
correlates. Findings in chronically ill and transplant
populations show that sociodemographic risk factors
include younger age,20–22 female gender,20,22,23 not
being married,24 a lower education level,24 unemploy-
ment,21 and being black or Hispanic.22,24–26 Patient-level
factors linked with CRMNA include patient-perceived
medication regimen-related financial burden,27 per-
ceived financial stress,28 financial insecurity regarding
healthcare,28 food insecurity,25,28 health beliefs,22,29
and private health insurance coverage.30 Linked to in-
surance coverage, OOPmedication expenditure14 is in-
trinsically linked to a country's healthcare system and
its medication coverage (eg, the presence of a third-
party copayment system).
To capture all modifiable factors that provide leverage
points for CRMNA-preventive or CRMNA-remedial
interventions, a theoretical perspective considering risk
factors occurring not only in patients31 but also at other
healthcare system levels (eg, transplant centers, health-
care systems)32 is desired. Therefore, we selected a
theoretical framework combining an ecological per-
spective32 with that of the Integrative Model of Behav-
ioral Prediction31 (Figure). On the basis of this model,
both patient-level factors and healthcare system char-
acteristics influence CRMNA. The relative contribu-
tions of multilevel factors to CRMNA variability remain
unknown.
This study had 3 aims: aim 1, to assess the preva-
lence of CRMNA to immunosuppressants in heart
transplant recipients internationally; aim 2, to identify
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correlates of CRMNA; and aim 3, to determine the pro-
portions of CRMNA variability attributable to patient-,
center-, and healthcare system–level factors.
Methods
Design, Sample, and Setting
This study was a secondary analysis of data collected
for the international cross-sectional multicenter BRIGHT
(Building Research Initiative Group: Chronic Illness
Management and Adherence in Transplantation33,34)
study. The methods and procedures of the BRIGHT
study have been described in detail elsewhere11,34 (see
also Clinicaltrials.gov ID: NCT01608477). The au-
thors of the BRIGHT study used a multistage sampling
approach and included 11 countries, 36 heart trans-
plant centers, and 1365 patients. Inclusion criteria for
heart transplant centers were as follows: (1) being lo-
cated in Europe, North America, South America, or
Australia and (2) having performed a minimum of 50
heart transplants for the previous 12 to 60 months.
Using a stratified random sampling approach based
on center size,34 patients were included if they fulfilled
the following criteria: (1) heart transplant recipient;
(2) 18 years or older at the time of inclusion; (3)
transplanted and followed up for routine care in one
of the participating transplant centers; (4) first trans-
plant; (5) single-organ transplant; (6) 1 to 5 years post
transplant; (7) no professional support in medication
taking, that is, a nurse or nursing aide or other health
personnel (excluding family members) in supporting a
heart transplant patient at home in preparing and/or
taking medication; (8) capacity to read, understand,
and sign written informed consent; and (9) provision
of written informed consent. Participants were ex-
cluded from the analysis if they omitted information
from any of the 3 items assessing CRMNA (see section
hereinafter). The study was approved centrally by the
ethics committee of KU Leuven in Belgium and by each
participating center's institutional review board. Before
data collection, the study was explained to each patient
and written informed consent was obtained.34
Variables and Measurement
Data used in this analysis were collected using 2 survey
instruments,34 one completed by the participating heart
transplant centers' transplant directors and the other
completed by their patients. The transplant director
questionnaire collected data on each center's structural
characteristics and practice patterns; the patient ques-
tionnaires assessedCRMNA, health behaviors, psychoso-
cial factors, and perceptions of care provided. Variables
were assessed using instruments specifically developed
for the BRIGHT study, as described hereinafter.34
Cost-Related Medication Nonadherence
Cost-related medication nonadherence was assessed at
patient level using 3 questions adapted from a previous
study by Wilson et al.9 Three cost-related behaviors
were measured: First, patients were asked how often
over the preceding 12 months they had not filled their
prescription for immunosuppressants because they were
too expensive (options: never, once, twice, 3–4 times,
5–6 times, 7 or more times). Second, they were asked
whether, over the past 12months, they had ever skipped
a dose of their immunosuppressants to make their pre-
scription last longer because of lack of money (options:
no, never; yes, sometimes; yes, often). Third, patients in-
dicated whether, over the past 12 months, because of
lack of money, they had reduced their dose of immuno-
suppressants (eg, by cutting pills in half ) so that the pre-
scribed supply would last longer (options: no, never; yes,
sometimes; yes, often). The responses were operational-
ized dichotomously as “no” (0) if patients answered
“never” on all 3 items and “yes” (1) if positive on any
of the three.
Multilevel Correlates of CRMNA
We assessed insurance coverage and OOP costs at the
country level and formal pretransplant financial-social
factors at the center level as healthcare system charac-
teristics. Assessing insurance coverage involved asking
patients whether their health insurance covered the
costs of immunosuppressants fully (options: yes, full
coverage; yes, partial coverage; or no coverage). The
OOP immunosuppressant cost assessment was derived
from a study that asked chronically ill patients their
monthly OOP medication expenses (0–20, 20.01–60,
60.01–110, and >110USD [adapted tomatch the respon-
dents' national currencies]).35 Pretransplant financial-
social evaluation was assessed by asking the transplant
directors whether their patients routinely underwent
formal financial-social evaluations (yes/no).
At the patient level, 5 correlates of CRMNAwere in-
cluded: intention to adhere, an adherence barrier, a health
belief, cost-related self-efficacy, and perceived financial
FIGURE. Theoretical framework (adapted).31,32
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burden (derived from the IntegrativeModel of Behavioral
Prediction).31 Intention, that is, the cognitive representa-
tion of a person's readiness to adhere, was assessed as
the average score for 3 items (Likert-type scale; range,
1–5 [“strongly disagree” to “strongly agree”]). The items
were as follows: (1) “My planning is to strictly follow the
prescription of my immunosuppressive medication,” (2)
“I will make sure that I never omit any intake of my im-
munosuppressive medications,” and (3) “I always intend
to take my immunosuppressive medications on time.”
The Cronbach a across these 3 items was 0.81. Cost as
a barrier to adherence was assessed by a single item ask-
ing patients how often they found it difficult to take
their IS medication because of the expense (Likert-
type scale; range, 1–5 [“never” to “always”]). To assess
cost-related self-efficacy, patients were asked how con-
fident they were that they would take their immuno-
suppressants exactly as prescribed despite their expense
(single item; 5-point Likert-style scale; range, 1–5 [“not
at all confident” to “completely confident”]). One health
belief was assessed: the belief in the benefits of a heart
transplant compared with adverse effects caused by ISs
(single item; Likert-type scale; range, 1–5 [“strongly dis-
agree” to “strongly agree”]). This belief was selected
based on previous research linking income to increased
worries and experiences of adverse effects.29 To assess
patients' perceived financial burden regarding their IS
regimens, they were asked whether they felt they had
enough money to pay for their ISs (1 item; Likert-style
scale; range, 1–4 [“more than enough” to “not enough”]).
We took this item from the SupportingMedication Ad-
herence in Renal Transplantation questionnaire.36
Furthermore, our CRMNAmodel included 6 socio-
demographic factors (Figure): age in years, gender, mar-
ital status (single, married/living with partner, divorced/
separated, widowed), ethnicity (white or other), educa-
tional level (primary/grade or no school, completed
high/secondary school, completed further education/
training, completed college/university), and employment
([self-]employed, looking for a job, on disability, retired,
other [eg, student, volunteer]).
Data Analysis
To address aim 1, variables were summarized by coun-
try and for the entire sample using descriptive statistics
including frequencies, percentages, and measures of
central tendency (means, medians) and dispersion (stan-
dard deviations, interquartile ranges), depending on mea-
surement levels and distribution of the variables. To
produce estimates that reflected the country-specific trans-
plant population sizes, CRMNAprevalence was weighted
for heart transplant population sizes at the national level.
Aim2 (to determineCRMNAcorrelates)was addressed
via simple logistic regression analyses testing the selected
variables' association with CRMNA. We accounted for
the cluster sampling via a random intercept at the trans-
plantation center level. To adjust for multiple testing, we
adapted probability values via the false discovery rate
method and reported these as q values.37
Achieving aim 3 meant disentangling the propor-
tions of CRMNA variability explainable at the patient,
center, and country levels. To do so, we added random
intercepts for country and (nested within that) center to
a logistic regression analysis, thereby allowing calculation
of the intracluster correlations for these levels.38 Although
the “insurance coverage” and “OOP costs” were mea-
sured at the patient level, a substantial part of their var-
iability likely results from country-level policy decisions;
therefore, we explored the magnitude of these 2 health-
care system factors' variability at the country level via
2 similar linear random-intercept regression analyses.
SAS 9.4 (SAS Institute Inc, Cary, North Carolina)
software was used for data analysis. The level of sig-
nificance was set at P < .05, with a false discovery rate
threshold of 5% (expressed as q values).37
Results
Sample Characteristics
In the 36 participating centers in 11 countries, 2523 patients
were eligible for inclusion. Of these, we randomly in-
vited 1677 to participate; 1397 responded by returning
questionnaires; and of this number, 1365 (81.4% of in-
vitees) answered all 3 CRMNA questions. The number
of participants is distributed as follows: 753 European,
472 North American, 49 Australian, and 40 Brazilian
participants. The dropout is due to refusals (n = 250),
death (n = 36), and missing data (n = 51). This group's
data were the basis of our analysis.
Of the 36 participating centers, 30 (83.3%) were
university hospitals and 32 (88.89%) were situated in
urban environments. On average, participating trans-
plant programs had existed for 27.6 ± 6.5 years. The
mean number of heart transplants performed for the
past 5 years was 125.5 ± 75.5.
Table 1 summarizes the patient sample characteris-
tics. Almost three-quarters of patients were male (n =
986, 72.6%); the mean age was 53.6 ± 13.2 years (range,
18–82 years); on average, posttransplantation time was
3.35 ± 1.38 years. More than two-thirds were married
or living with a partner (n = 938). Approximately one-
quarter (26.3%)were employed (n = 357), andmostwere
white (n = 1162, 88.1%). Full insurance coverage for IS
drugs was available to 59%, and 62.5% (n = 838) re-
ported monthly OOP costs of less than 20 USD.
International Prevalence and Variability of
Cost-Related Nonadherence
to Immunosuppressants
The overall weighted CRMNA prevalence was 2.6%
(n = 36; Table 2), ranging from 0% in Switzerland and




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CRMNA Prevalence After Heart Transplantation 7
Brazil to 9.8% in Australia. Examining our 3 studied
CRMNAaspects, we found that, overall, 1.5% reported
unfilled prescriptions (highest weighted rates: Australia,
5.8%; andCanada, 4.3%), 2.1% skipped doses (highest
weighted rates: Australia, 5.9%; andUnited States, 4.5%),
and 1.5% reduced doses because of cost (highest weighted
rates: United States, 3%; and Canada, 2.6%) (Table 2).
Furthermore, we observed that 35.4% of patients with
CRMNA (ie, in the United States, Australia, France, Spain,
Canada, and the United Kingdom) exhibited at least 2 of
the 3 cost-related adherence behaviors, with 8.3% of pa-
tients exhibiting all 3 (ie, in the United States and Canada).
Multilevel Correlates of CRMNA
Table 2 lists healthcare system– and patient-level factors
overall andbycountry.Regardinghealthcare systemfactors,
except for Brazil, countries whose centers performed formal
pretransplant financial-social evaluations, namely, Canada,
the United States, Australia, and Switzerland, were those
where patients reported the highest OOP costs. At least
15% of these 4 countries' patients reported monthly
OOP costs of more than 110 USD, and between 39.2%
(Switzerland) and 86% (Australia) of patients paid part
or all of their IS costs.
Table 1 shows the results of our univariable analyses
on potential CRMNA correlates. Three risk factors
emerged as significant: higher perceived financial burden
(odds ratio, 2.15; 95% confidence interval, 1.55–2.99; q
< 0.0001), cost as a barrier to medication adherence
(odds ratio, 2.60; 95% confidence interval, 1.66–4.07;
q = 0.0002), and being single (comparedwith beingmar-
ried or livingwith a partner) (odds ratio, 2.29; 95% con-
fidence interval, 1.17–4.47; q = 0.05). Three factors
were protective: higher intention to adhere to immuno-
suppressants (odds ratio, 0.44; 95% confidence interval,
0.31–0.63; q < 0.0001), higher cost-related self-efficacy
(odds ratio, 0.54; 95% confidence interval, 0.43–0.67;
q < 0.0001), and higher belief in the benefits of heart
transplantation compared with the adverse effects of
immunosuppressants (odds ratio, 0.70; 95% confidence
interval, 0.57–0.87; q = 0.009). Lower CRMNAwas also
found in whites compared with other racial groups (odds
ratio, 0.37; 95% confidence interval, 0.19–0.74; q = 0.02).
Regarding interaction effects,we foundhigherprobabilities
of CRMNA in cases where high OOP expenses accompa-
nied higher perceived financial burden (P = .03, q = 0.08).
Cost-RelatedMedication Nonadherence Variability
Explained by Factors at the Various Healthcare
System Levels
The percentage of CRMNA variability explainable at the
country levelwas 4.8% (P= .31,q=0.40),with the center
level accounting for 13.8% (P= .08,q=0.16). This implies
that most variability (81.4%) was at the patient level.
The percentages of “insurance coverage” and “OOP
cost” variability attributable to country-level differ-
ences were, respectively, 60.1% and 24.1%.
Discussion
To our knowledge, this is the first study to investigate
prevalence and multilevel correlates of CRMNA in an
adult heart transplant population. It adds to the in-
sights obtained from the 2013 and 2014 Common-
wealth Fund International Health Policy Surveys13,14
and from country-specific reports on CRMNA in
chronically ill populations39 in the United States,
Canada, and Brazil.13,19,30,40–42 The BRIGHT study fo-
cuses on medication adherence and CRMNA, whereas
this substudy is focused on CRMNA only, a part of
medication adherence.
This study's strengths include the use of a theoretical
framework including both patient31 and healthcare sys-
tem32 factors. Compared with the 12.5% prevalence of
CRMNA found by Schoen et al,14,40 who used 2 of our
3 items in a large international sample of chronically ill
patients, our heart transplant sample indicated surpris-
ingly little CRMNA (2.6%). However, our sample's
intercountry variability was similar to what the Com-
monwealth surveys indicated.13,14 Factors linked to
CRMNA were intention to adhere, perceived financial
burden, cost as a barrier to medication adherence, cost-
related self-efficacy, the tested health belief, marital sta-
tus (single), and race—all of which were situated at the
patient level of our model.
Our sample's CRMNAwas considerably lower than
those of other chronically ill samples,14 possibly be-
cause heart transplant recipients prioritize adherence
to immunosuppressants higher than to other medica-
tions. Although CRMNA represents only a small part
of overall nonadherence, the transplant literature con-
sistently shows lower nonadherence to immunosup-
pressants than to other medications.1,2,43 In addition,
more financial support is available for immunosuppres-
sants in transplant recipients (eg, drug vouchers), and
because IS nonadherence is a known risk factor con-
cerning solid organ transplantation outcomes,7 care
teams work particularly hard to help patients adhere
to those regimens.44 Some centers in the United States
offer patients financial support programs to address
the financial hurdle of drug prescription.45,46
Concerning international CRMNA variability, we
found the highest rates in Australia (9.8%), Canada
(6.8%), and the United States (5.6%). The 201314
and 201413 Commonwealth surveys reported, respec-
tively, 29% and 16.8% CRMNA prevalence in chron-
ically ill patients and older chronically ill adults in the
United States, 14% and 6.8% in Australia, and 13%
and 8.3% in Canada.13,14 The United States typically
has the highest nonadherence rates not only formedica-
tion40 but also for other health behaviors25,47; how-
ever, it ranked only third in our study. We only can
hypothesize whether this observation might be due to
patients with better socioeconomic or insurance status
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having more favorable chances for selection for trans-
plantation, as has been shown in renal transplant
recipients. Admittedly, once transplanted, many trans-
plant programs have financial assistance programs to
support patients to pay for their transplant and
immunosuppressants.48,49
In our theoretical model, patient-level factors were
significantly associated with CRMNA. In line with an
earlier finding that being married is a protective fac-
tor, we found that being single was a risk factor for
CRMNA.24 The fact that divorced/separated orwidowed
persons did not showany tendency for increasedCRMNA
may suggest the latter groups are not at the same finan-
cial disadvantage of singles andmay have sources of in-
come or savings singles do not have. Race was also
significantly associated with CRMNA. The literature,
however, only partially supports this link.22,24,26 Con-
versely, our findings did not corroborate sociodemo-
graphic factors reported elsewhere, for example, younger
age,20–22 female gender,20,21,23,27 lower educational level,24
and unemployment.21 Overall, however, this study con-
firmed the importance of patient-level variables derived
from the Integrative Model of Behavioral Prediction.31
More specifically, we found significant correlations be-
tween CRMNA and intention to adhere, cost-related
self-efficacy, cost-related barriers, and health belief. To
our knowledge, of these factors, only the CRMNA–
health belief link has previously been tested in chroni-
cally ill samples.22,29 Perceived financial burden, another
significant correlate in our study, has previously been
associatedwith CRMNA in chronically ill groups.27 In-
deed, previous evidence also linked CRMNA to other
potential influences on patients' perceived ability to fi-
nance their medication regimens, including perceived
financial stress,19,28 financial insecurity regarding health-
care,28 and food insecurity.28
Although most CRMNA variability was explained
by patient-level factors, several (nonsignificant) results
also suggested center- and country-level connections. The
center-level suggestions might reflect pretransplantation
financial evaluation practice patterns or underimplemen-
tation of financial support programs for medication in
settings with high OOP8,50 expenses (not assessed here).
The country level encompasses all healthcare policy
measures and practices concerningmedication coverage.
Our lack of significant correlations between CRMNA
and any of the studied healthcare system factors con-
trasts with earlier findings relating it to OOP14 expenses
and insurance coverage.8,30 However, we did note that
these factors' relevance increased alongside perceived fi-
nancial burden.
In Australia, Canada, and the United States, sub-
stantial numbers of patients reported only partial cov-
erage of IS medications, leading to comparatively high
OOP costs. Our country-level estimations of these ex-
penses varied similarly to those observed by Schoen
et al.14 Among the 5 countries with the highest OOP
costs and high median per capita income (ie, Switzerland,
Norway, the United States, Australia, and Canada),14,51
however, only Australia, the United States, and Canada
showed high CRMNA rates. This discrepancy has been
explained, at least between Switzerland and the United
States, by the fact that, whereas Switzerland's insurance
system is transparent regarding deductibles and cost-
sharing, that of the United States is dauntingly complex:
insurance disputes are commonplace, and continuity of
insurance is not guaranteed.40 Similar complications (eg,
payment denials or lower-than-expected coverage) have
been reported inAustralia, whichmay explainAustralians'
high CRMNA prevalence.40
As for the practical implications of our results, despite
CRMNA's low overall prevalence, it should certainly be
on every transplant clinician's radar, and in Australia,
Canada, and the United States, its high prevalence warrants
corrective action. From 2010 to 2013, Commonwealth sur-
veys of all 3 countries showed increases regarding both
CRMNAprevalence andmonthlyOOPexpenses (per capita
spending > 1000 USD) in chronically ill adults, with
each year's highest CRMNAprevalence (21%) occurring
in the United States.14
Overall, in addition to overall medication adherence,
the fifth vital sign in transplant follow-up care,52 CRMNA
must bemonitored as a serious health concern. The 3ques-
tionsweused to assessCRMNAserve this purposewell. In
the United States, center-specific programs (eg, at Kaiser
Permanente or Virginia Commonwealth University)45,46
can provide guidance as well as specific financial support
programs where high OOPmedication costs apply.8,50 In
addition, Patel et al28 correlated asking one's doctor for
less costlymedicationwith a lower probability of CRMNA,
and a 2011 randomized controlled trial demonstrated the
clinical and financial effects of full insurance coverage for
preventive medication after myocardial infarction.53 This
latter study is relevant in all contexts, but particularly in
those with high OOP costs.14
Although CRMNA affects all chronically ill groups,19
the high specificity of IS treatment and the heart trans-
plant population of the BRIGHT study limit direct
application of our findings to other cardiovascular pop-
ulations. Further research using the BRIGHTmethodol-
ogy could increase CMRNA-related knowledge on a
range of cardiovascular populations internationally.
For now, though, particularly in areas with high OOP
medication expenses, all cardiovascular nurses and other
healthcare professionals should be vigilant regarding
CRMNA. Determining whether patients' resources cover
their medication regimen could be guided by the ques-
tions used here. Moreover, the same nurses should fa-
miliarize themselves with and refer CRMNA patients
to financial support programs for medication.8,50
Various limitations affect the current study. We
assessed CRMNA in view of immunosuppressants but
CRMNA Prevalence After Heart Transplantation 9
not to othermedications. As heart transplant recipients'
medication regimens include treatments for both pre-
transplant comorbidities and those that develop post
heart transplantation, this population has a heavy
treatment burden1; therefore, authors of further re-
search should focus on other aspects of their medica-
tion regimens beyond immunosuppressants. The focus
of the BRIGHT studywas on the posttransplant period,
which provides only limited information. Authors of
future research could focus on pretransplant or re-
peated assessment of CRMNApost transplant. In addi-
tion, our cross-sectional study design precludes causal
inferences, the use of self-reporting to assess CRMNA
as well as covariates might have introduced measure-
ment error, and the low proportion of patients with
CRMNA left us with insufficient statistical power to
perform multivariable analyses.
Conclusion
The authors of this study found that heart transplant
recipients' overall CRMNA prevalence (2.6%) is lower
than chronically ill patients' CRMNA prevalence. We
observed considerable intercountry variability inCRMNA.
Our analyses identified similar CRMNA-related, patient-
related factors (ie, intention to adhere, perceived financial
burden, cost as a barrier to medication adherence, cost-
related self-efficacy, health belief regarding medication
benefits, marital status [single], and ethnicity [ie, not
being white]) than those reported in the CMRNA liter-
ature studying other chronically ill populations.
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